---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-26-000002"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:10:54.814425+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xencor reports $611M cash; outlines 2026 pipeline milestones for XmAb candidates

## Summary
- Unaudited cash, equivalents & marketable debt securities ~$611M as of Dec 31, 2025 vs $706.7M a year ago.
- Cash expected to fund operations through 2028 based on current plans.
- XmAb819 (ENPP3xCD3) for ccRCC: 25% partial response; pivotal study planned in 2027.
- XmAb541 (CLDN6xCD3) for gynecologic/germ cell tumors: confirmed partial responses in 3 of 9 patients; pivotal study planned in 2027.
- Autoimmune pipeline: Phase 1b plamotamab in RA, Phase 1 XmAb657 in IIM, Phase 2b XENITH-UC, and first-in-human TL1AxIL23p19 in 2H26.

## SEC filing metadata
- accession: 0001326732-26-000002
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000002/0001326732-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673226000002/xncr-20260108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-26-000002
- JSON: https://secwatch.observer/filing/0001326732-26-000002.json
- Plain text: https://secwatch.observer/filing/0001326732-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.